TargetBeta
TIGIT
T cell immunoreceptor with Ig and ITIM domains · also FLJ39873, DKFZp667A205, VSIG9, VSTM3 · V-set domain containing
4 programs in company-led studies act on TIGIT, from 4 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| rilvegostomig | AstraZeneca | phase 3 | 2423 running | PDCD1 | a judged reading |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 1513 running | PDCD1 | NCIt |
| domvanalimabrule | Gilead Sciences | phase 3 | 106 running | – | NCIt |
| BC008-1Arule | Sichuan Luzhou Buchang Biopharmaceutical | phase 1 | 22 running | – | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Carcinoma, Hepatocellular, 2 programs
- Squamous Cell Carcinoma of Head and Neck, 2 programs
- Adenocarcinoma Of Esophagus, 1 program
- Biliary Tract Neoplasms, 1 program
- Carcinoma, Neuroendocrine, 1 program
- Esophageal Neoplasms, 1 program
- Glioblastoma, 1 program
- Lymphoma, 1 program
- Stomach Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2027domvanalimab · Gilead Sciences · phase 3 · NCT06727565
- Apr 2027nilvanstomig · Suzhou Zelgen Biopharmaceuticals · phase 3 · NCT06903377
- May 4, 2027rilvegostomig · AstraZeneca · phase 3 · NCT04379596
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.